Repurposing the FDA-approved raloxifene to potentiate gemcitabine cytotoxicity in pancreatic cancer

被引：0
|
作者：
Trinh, Jessica [1 ]
Badejo, Adeleke [2 ]
Love, Quintin [2 ]
True, Heather [2 ]
Rao, Deepa [2 ]
Malhotra, Ashim [2 ]
机构：
[1] Pacific Univ, Forest Grove, OR USA
[2] Pacific Univ, Sch Pharm, Hillsboro, OR USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2018年 / 255卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
1212
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Repurposing the FDA-Approved Pinworm Drug Pyrvinium as a Novel Chemotherapeutic Agent for Intestinal Polyposis
    Li, Bin
    Flaveny, Colin A.
    Giambelli, Camilla
    Fei, Dennis Liang
    Han, Lu
    Hang, Brian I.
    Bai, Feng
    Pei, Xin-Hai
    Nose, Vania
    Burlingame, Oname
    Capobianco, Anthony J.
    Orton, Darren
    Lee, Ethan
    Robbins, David J.
    PLOS ONE, 2014, 9 (07):
  • [42] Repurposing FDA-approved drugs as HIV-1 integrase inhibitors: an in silico investigation
    Ha, Christopher Heng Xuan
    Lee, Nung Kion
    Rahman, Taufiq
    Hwang, Siaw San
    Yam, Wai Keat
    Chee, Xavier Wezen
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (06): : 2146 - 2159
  • [43] Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study
    Jose, Sandra
    Devi, Sreevidya S.
    Sajeev, Anjana
    Girisa, Sosmitha
    Alqahtani, Mohammed S.
    Abbas, Mohamed
    Alshammari, Abdulrahman
    Sethi, Gautam
    Kunnumakkara, Ajaikumar B.
    BIOSCIENCE REPORTS, 2023, 43 (03)
  • [44] The Repurposing of FDA-Approved Drugs as FtsZ Inhibitors against Mycobacterium tuberculosis: An In Silico and In Vitro Study
    Tovar-Nieto, Andrea Michel
    Flores-Padilla, Luis Enrique
    Rivas-Santiago, Bruno
    Trujillo-Paez, Juan Valentin
    Lara-Ramirez, Edgar Eduardo
    Jacobo-Delgado, Yolanda M.
    Lopez-Ramos, Juan Ernesto
    Rodriguez-Carlos, Adrian
    MICROORGANISMS, 2024, 12 (08)
  • [45] Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
    Dylan Jones
    Clarissa A. Whitehead
    Marija Dinevska
    Samuel S. Widodo
    Liam M. Furst
    Andrew P. Morokoff
    Andrew H. Kaye
    Katharine J. Drummond
    Theo Mantamadiotis
    Stanley S. Stylli
    Molecular and Cellular Biochemistry, 2023, 478 : 1251 - 1267
  • [46] Leber's hereditary Optic Neuropathy: repurposing FDA-approved molecules to identify potential leads
    Datta, Sandipan
    Cortopassi, Gino
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [47] Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2
    Ku, Keun Bon
    Shin, Hye Jin
    Kim, Hae Soo
    Kim, Bum-Tae
    Kim, Seong-Jun
    Kim, Chonsaeng
    JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2020, 30 (12) : 1843 - 1853
  • [48] Elacestrant: a new FDA-approved SERD for the treatment of breast cancer
    Bhatia, Neha
    Thareja, Suresh
    MEDICAL ONCOLOGY, 2023, 40 (06)
  • [49] Repurposing FDA-approved drugs to treat chemical weapon toxicities: Interactive case studies for trainees
    Aleksunes, Lauren M.
    Gray, Joshua P.
    Meshanni, Jaclynn
    Laskin, Jeffrey D.
    Laskin, Debra L.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2024, 12 (04):
  • [50] Elacestrant: a new FDA-approved SERD for the treatment of breast cancer
    Neha Bhatia
    Suresh Thareja
    Medical Oncology, 40
12345